

Amend the claims to read as follows:

Cancel claim 2.

a¹ 1. (Amended) An isolated KIAA0175 inhibitor wherein said KIAA0175 inhibitor is an anti-sense molecule.

a² 3. (Amended) The isolated KIAA0175 inhibitor of claim 1 wherein said anti-sense molecule or the complement thereof comprises at least 17 consecutive nucleic acids of the sequence of SEQ ID NO:9.

a³ 5. (Amended) The isolated KIAA0175 inhibitor of claim 2 wherein said anti-sense molecule comprises a nucleic acid sequence of SEQ ID NO:1.

a⁴ 20. (Amended) A composition, comprising a therapeutically effective amount of at least one KIAA0175 inhibitor in a pharmaceutically acceptable carrier wherein at least one of said KIAA0175 inhibitors is an antisense molecule.

a⁵ 25. (Amended) The composition of claim 22 wherein said anti-sense molecule comprises a nucleic acid sequence of SEQ ID NO:1.

Remarks

In response to the Restriction Requirement dated October 2, 2003, applicants have elected Group I, claims 1-5 and 20-26 and the species of SEQ ID NO:1. Claim 2 has been cancelled. Claims 1, 3, 5, 20 and 25 have been amended to reflect the election of Group I (antisense) and SEQ ID NO:1. No new matter has been added.